Sarepta Therapeutics Inc.

09/27/2021 | Press release | Distributed by Public on 09/27/2021 06:35

Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions[...]